• SHARE

Ten months ago, the results of large clinical trials appeared almost too good to be true: Two messenger RNA vaccines reduced symptomatic COVID-19 cases by more than 90% in almost every group that got them.

Now, subtle differences between the Pfizer Inc.-BioNTech SE and Moderna Inc. vaccines are emerging across patient groups over time. One small U.S. study found waning levels of antibodies with Pfizer’s vaccine, particularly in an older group of people. And a larger study from Belgium found that Moderna’s shot may generate more antibodies than Pfizer’s.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)